ASAyush Shukla

Ayush Shukla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayush Shukla has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of no-reflow phenomenon in patients with ST-segment- elevation myocardial infarction undergoing primary PCI vs. pharmaco-invasive strategy: a single-centre study

    by Ayush Shukla, Awadhesh Kumar Yadav, Akhil Kumar Sharma, Gaurav Kumar Chaudhary, Umesh Chandra Tripathi, Sharad Chandra, Rishi Sethi, Akshyaya Pradhan, Pravesh Vishwakarma, Monika Bhandari, et al.

    Background: The no-reflow phenomenon after percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) represents a major barrier to successful reperfusion, leading to adverse outcomes despite epicardial vessel patency. Comparative evidence regarding its incidence and clinical consequences between primary PCI and pharmaco-invasive PCI remains scarce. Aim: The study aimed to compare the incidence of the no-reflow phenomenon in patients undergoing pharmaco-invasive PCI versus primary PCI, and to evaluate the short-term clinical outcomes of patients with no-reflow at three months post-procedure. Methods: In this prospective, single centre, observational study, STEMI patients presenting within 24 h of symptom onset were enrolled at a tertiary care centre. Patients experiencing no-reflow were categorized into Group A (primary PCI; n = 92) and Group B (pharmaco-invasive PCI; n = 192). Baseline demographics, comorbidities, angiographic characteristics, and outcomes were analysed. The primary outcome was the incidence of major adverse cardiac events at three months. Results: Among 857 patients undergoing primary PCI and 2,976 undergoing pharmaco-invasive PCI, the incidence of no-reflow was significantly higher in the primary PCI group (10.7% vs. 6.5%). Patients in Group A were older (58.9 ± 13.6 vs. 54.4 ± 11.4 years; P = 0.004) and more frequently diabetic (55.4% vs. 41.6%; P = 0.029), whereas hypertension was more prevalent in Group B (42.7% vs. 13.0%; P < 0.001). Baseline TIMI 0 flow was more common in Group A (79.3% vs. 24.5%; P < 0.001). After PCI, final TIMI 3 flow rates were comparable (85.9% vs. 89.6%; P = 0.361). In-hospital complications and three-month outcomes were similar between two groups: death (4.3% vs. 5.2%), revascularization (4.3% vs. 4.7%), and rehospitalization (5.4% vs. 3.1%) (all P > 0.05). Conclusion: No-reflow was more frequent after primary PCI, particularly in older, diabetic, and late-presenting patients with baseline TIMI 0 flow. Both reperfusion strategies achieved comparable short-term clinical outcomes in no-reflow patients. Pharmaco-invasive PCI may mitigate the risk of no-reflow in selected STEMI patients while maintaining equivalent early prognosis.

  • Open Access

    Prognostic significance of carotid intima-media thickness in patients with coronary slow flow: A systematic review and meta-analysis

    by Akhil Kumar Sharma, Ayush Shukla, Gaurav Chaudhary, Sharad Chandra, Umesh Chandra Tripathi, Safal Safal, Satyavir Yadav, Awadhesh Kumar Sharma

  • Incidence and predictors of temporary pacemaker implantation–induced cardiac perforation

    by Sudhanshu Kumar Dwivedi, Akhil Sharma, Gaurav Chaudhary, Sharad Chandra, Monika Bhandari, Pravesh Vishwakarma, Akshyaya Pradhan, Rishi Sethi, Ayush Shukla, Abhishek Singh, et al.


  • Open Access

    Reliability of Fractional Flow Reserve in Non-Infarct-Related Arteries in ST-Segment Elevation Myocardial Infarction Patients Undergoing a Pharmaco-Invasive Approach

    by Ayush Shukla, Sudhanshu K Dwivedi, Sharad Chandra, Gaurav Chaudhary, Akhil Sharma, Rishi Sethi, Akshyaya Pradhan, Pravesh Vishwakarma, Monika Bhandari, Abhishek Singh

    Objectives We investigated the reproducibility of fractional flow reserve (FFR) of significant stenoses (>= 70% narrowing) in the non -infarct related artery (NIRA) during the pharmaco-invasive percutaneous coronary intervention (PCI) in patients with ST -segment elevation myocardial infarction (STEMI) within 24 hours of thrombolysis and at a follow up of 2-3 weeks. Background STEMI with multivessel disease has worse outcomes. The benefits of FFR-directed PCI of NIRA at the time of primary PCI are yet controversial. Assessing the hemodynamic severity of the NIRA may help in deciding the management strategy of these lesions, save time, and avoid complications. Methods Thirty-one patients undergoing PCI for STEMI under a pharmaco-invasive approach were prospectively recruited. The FFR measurements in 34 stenoses (>= 70% diameter stenosis) were obtained immediately after PCI of the culprit stenosis and were repeated at a mean follow-up of 17.6 +/- 3.55 (14-21) days. In addition, time to thrombolysis, time from symptom onset to PCI, left ventricular ejection fraction (LVEF), quantitative coronary angiographic measurements of the non -culprit stenoses, and thrombolysis in myocardial infarction (TIMI) flow were recorded. Results There was a significant change in FFR values at follow-up as compared to baseline (0.78 +/- 0.08 (0.68-0.93) to 0.77 +/- 0.08 (0.67-0.93)) (p = 0.014). In four of the lesions, the FFR values differed by >0.05 at follow-up. The follow-up FFR values led to a change in the management strategy in 5 out of 31 patients (15%) of the lesions. The TIMI flow, percentage diameter stenosis, minimum lumen diameter, and LVEF did not change. There were no predictors of this change in FFR values. Conclusions During the acute phase of STEMI, the severity of non -culprit coronary artery stenoses can not be reliably assessed by FFR. The prolonged jeopardized state of myocardium in pharmaco-invasive PCI as compared to primary PCI seems to be responsible.


  • Open Access

    Correlation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography

    by Sharad Chandra, Saurabh Nagar, Ayush Shukla, Gaurav Chaudhary, Akhil Sharma, Akshyaya Pradhan, Monika Bhandari, Pravesh Vishwakarma, Rishi Sethi, Varun Shankar Narain, et al.


  • Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients

    by Anil Kumar Tripathi, Ayush Shukla, Sanjay Mishra, Yogendra Singh Yadav, Deependra Kumar Yadav

    Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterised by isolated thrombocytopenia (peripheral blood platelet count 9/L) in the absence of other causes or disorders that may be associated with thrombocytopenia. The upfront treatment in newly diagnosed ITP patients is steroids; however, about one-third patients do not respond, and require other treatment, including IVIg, anti-D, or splenectomy. Previous studies have shown decreased platelet production in some ITP patients, aside from the evidence of enhanced platelet destruction. Thrombopoietin receptor agonists (TPO-RA), such as eltrombopag have been shown to provide good response in steroid non-responsive chronic ITP patients. We have studied response to eltrombopag in 25 newly diagnosed steroid non-responsive ITP patients; 80 % patients showed response at the end of 1 month, and 76 % sustained response at the end of 3 months. The platelet count rose from a mean value of 17.5 ± 3.6–152.5 ± 107.9 × 109/L at the end of 1 month. Our results suggest a possible role of eltrombopag in newly diagnosed steroid non-responsive ITP patients. However, our study is limited in that it is a single-centre study, with a small sample size, and lacks a long-term safety profile. Our findings highlight the potential value of a larger prospective study on the upfront use of TPO-RA in patients of ITP.


  • Open Access

    Pure Red Cell Aplasia: A Rare Complication of Isoniazid Therapy

    by Ayush Shukla, Sanjay Mishra, Mili Jain, Anil Kumar Tripathi